ZEALAND PHARMA A/S ZLDPF news, videos and press releases
For more news please use our advanced search feature.
ZEALAND PHARMA A/S ZLDPF - More news...
ZEALAND PHARMA A/S ZLDPF - More news...
- Correction to Company announcement – No. 23 / 2024
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024
- Total number of shares and voting rights in Zealand Pharma at March 31, 2024
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
- Zealand Pharma major shareholder announcement: Van Herk Investments
- Zealand Pharma's Annual General Meeting 2024
- Zealand Pharma major shareholder announcement: Polar Capital
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- New Employee Elected Directors to the Board of Zealand Pharma A/S
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
- Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
- Zealand Pharma convenes its Annual General Meeting 2024
- Zealand Pharma Announces Financial Results for the Full Year 2023
- Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
- Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
- Total number of shares and voting rights in Zealand Pharma at January 31, 2024
- Zealand Pharma major shareholder announcement: Van Herk Investments
- Zealand Pharma major shareholder announcement: J O Hambro Capital Management
- Zealand Pharma major shareholder announcement: J O Hambro Capital Management
- Zealand Pharma completes registration of capital increase
- Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
- Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
- Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
- Total number of shares and voting rights in Zealand Pharma at December 29, 2023
- U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
- Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
